Clinical Trial Update: Denileukin Diftitox in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial of denileukin diftitox for relapsed or refractory non-Hodgkin lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• ONTAK (denileukin diftitox)

Snippet

Sponsor: Jonsson Comprehensive Cancer Center | Conditions: Lymphoma | Phase 2 | Status: COMPLETED